Economic and clinical impact of multiple myeloma to managed care.

  title={Economic and clinical impact of multiple myeloma to managed care.},
  author={Richard Cook},
  journal={Journal of managed care pharmacy : JMCP},
  volume={14 7 Suppl},
  • Richard Cook
  • Published 2008 in Journal of managed care pharmacy : JMCP
BACKGROUND Because of the development of novel agents such as immunomodulators, proteasome inhibitors, and bisphosphonates, the standards of care for the multiple myeloma (MM) patient have changed. The costs associated with current and emerging therapies, as well as supportive care, are significant and pose a tremendous financial burden to both patients and managed care. OBJECTIVE To review the economic impact of MM and to weigh the advantages and disadvantages of current treatments in… CONTINUE READING
10 Citations
18 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 18 references

for lymphoid malignancies : clinical and economic outcomes from the Nationwide Inpatient Sample

  • KR Meehan, T Fitzmaurice, L Root, E Kimtis, L Patchett, J Hill
  • Cancer
  • 2008

An economic perspective on treatment options in multiple myeloma

  • R. Cook
  • Managed Care Oncol. Spring
  • 2007

International Myeloma Foundation

  • L. Lederman
  • ASCO
  • 2007

Similar Papers

Loading similar papers…